Article
A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
Scientific reports - 25 Nov 2020
Lu Mei, Wu Kuan-Han Hank, Trudeau Sheri, Jiang Margaret, Zhao Joe, Fan Elliott
Abstract excerpt
Tumor mutational burden (TMB) is associated with clinical response to immunotherapy, but application has been limited to a subset of cancer patients. We hypothesized that advanced machine-learning and proper modeling could identify mutations that classify patients most likely to derive clinical benefits. Training data: Two sets of public whole-exome sequencing (WES) data for metastatic melanoma. Validation data:...
Topics
Join the communities discussing this publication.